Bimal Shah
Director/Board Member at ANEBULO PHARMACEUTICALS, INC.
Bimal Shah active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Director/Board Member | 2023-10-04 | - |
| Independent Dir/Board Member | 2023-10-04 | - | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Director of Finance/CFO | 2012-09-04 | - |
| Treasurer | 2012-09-04 | - |
Career history of Bimal Shah
Former positions of Bimal Shah
| Companies | Position | Start | End |
|---|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2010-05-31 | 2020-12-31 |
Training of Bimal Shah
| Stanford University | Graduate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 1 |
| Director of Finance/CFO | 1 |
| Treasurer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Stock Market
- Insiders
- Bimal Shah
- Experience
